Search

Your search keyword '"Von Hoff, D D"' showing total 647 results
Start Over Author "Von Hoff, D D"
647 results on '"Von Hoff, D D"'

3. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

Author

Chiorean, E. G., Von Hoff, D. D., Reni, M., Arena, F. P., Infante, J. R., Bathini, V. G., Wood, T. E., Mainwaring, P. N., Muldoon, R. T., Clingan, P. R., Kunzmann, V., Ramanathan, R. K., Tabernero, J., Goldstein, D., McGovern, D., Lu, B., and Ko, A.

Published
2016
Full Text
View/download PDF

11. Treatment of advanced squamous cell carcinoma of the head and neck with isotretinoin: a phase II randomized trial.

Author

Lippman, S M, Kessler, J F, Al-Sarraf, M, Alberts, D S, Itri, L M, Mattox, D, Von Hoff, D D, Loescher, L, and Meyskens, F L

Subjects
Adult, Aged, Carcinoma, Squamous Cell: drug therapy, pathology, Drug Evaluation, Female, Head and Neck Neoplasms: drug therapy, pathology, Humans, Isotretinoin, Male, Methotrexate: adverse effects, therapeutic use, Middle Aged, Random Allocation, Tretinoin: adverse effects, therapeutic use, head and neck cancer, retinoids, squamous cell carcinomaisotretinoin, methotrexate, advanced cancer, clinical article, female, head and neck carcinoma, human, intramuscular drug administration, male, phase 2 clinical trial, priority journal, squamous cell carcinoma, Adult, Aged, Carcinoma, Squamous Cell, Drug Evaluation, Female, Head and Neck Neoplasms, Human, Isotretinoin, Male, Methotrexate, Middle Age, Random Allocation, Support, Non-U.S. Gov't, Support, U.S. Gov't, P.H.S., Tretinoin
Abstract

Retinoids, the analogs of vitamin A, are active in vitro and in vivo against squamous cell carcinoma in animals and against certain epithelial precancers and cancers in humans. These data led us to design a prospective, multi-institutional, randomized phase II trial of isotretinoin in advanced head and neck squamous cell carcinoma. We randomly assigned 40 patients to receive isotretinoin or methotrexate, the best-studied and most active single agent for this disease. Overall, the study patients had extremely poor prognoses, i.e., low performance statuses and recurring disease after surgery and/or irradiation. Three objective responses (16%), including one complete response, occurred in the 19 evaluable isotretinoin-treated patients. Only one minor response (5%) occurred in the methotrexate-treated group. Toxicity occurred with both drugs, but was manageable and never life threatening in the retinoid group. These results and the established activity of retinoids in oral leukoplakia (a precursor of head and neck cancer) indicate the need for further study of this class of drugs in head and neck cancer.

Published
1988

17. m-AMSA: A New Anticancer Agent

Author

Rozencweig, M., Von Hoff, D. D., Legha, S. S., Cysyk, R. L., Muggia, F. M., Allfrey, V. G., editor, Allgöwer, M., editor, Berenblum, I., editor, Bergel, F., editor, Bernard, J., editor, Bernhard, W., editor, Blokhin, N. N., editor, Bock, H. E., editor, Braun, W., editor, Bucalossi, P., editor, Chaklin, A. V., editor, Chorazy, M., editor, Cunningham, G. J., editor, Della Porta, G., editor, Denoix, P., editor, Dulbecco, R., editor, Eagle, H., editor, Eker, R., editor, Good, R. A., editor, Grabar, P., editor, Harris, R. J. C., editor, Hecker, E., editor, Herbeuval, R., editor, Higginson, J., editor, Hueper, W. C., editor, Isliker, H., editor, Kieler, J., editor, Kirsten, W. H., editor, Klein, G., editor, Koprowski, H., editor, Koss, L. G., editor, Macbeth, R. A., editor, Martz, G., editor, Mathé, G., editor, Mühlbock, O., editor, Old, L. J., editor, Potter, V. R., editor, Sabin, A. B., editor, Sachs, L., editor, Saxén, E. A., editor, Schmidt, C. G., editor, Spiegelman, S., editor, Szybalski, W., editor, Tagnon, H., editor, Tissières, A., editor, Uehlinger, E., editor, Wissler, R. W., editor, Rentchnick, P., editor, Senn, H. J., editor, Mathé, Georges, editor, and Muggia, Franco M., editor

Published
1980
Full Text
View/download PDF

18. N-(Phosphonacetyl)-L-Aspartate (PALA): Current Status

Author

Rozencweig, M., Abele, R., Piccart, M., Von Hoff, D. D., Muggia, F. M., Allfrey, V. G., editor, Allgöwer, M., editor, Berenblum, I., editor, Bergel, F., editor, Bernard, J., editor, Bernhard, W., editor, Blokhin, N. N., editor, Bock, H. E., editor, Braun, W., editor, Bucalossi, P., editor, Chaklin, A. V., editor, Chorazy, M., editor, Cunningham, G. J., editor, Della Porta, G., editor, Denoix, P., editor, Dulbecco, R., editor, Eagle, H., editor, Eker, R., editor, Good, R. A., editor, Grabar, P., editor, Harris, R. J. C., editor, Hecker, E., editor, Herbeuval, R., editor, Higginson, J., editor, Hueper, W. C., editor, Isliker, H., editor, Kieler, J., editor, Kirsten, W. H., editor, Klein, G., editor, Koprowski, H., editor, Koss, L. G., editor, Macbeth, R. A., editor, Martz, G., editor, Mathé, G., editor, Mühlbock, O., editor, Old, L. J., editor, Potter, V. R., editor, Sabin, A. B., editor, Sachs, L., editor, Saxén, E. A., editor, Schmidt, C. G., editor, Spiegelman, S., editor, Szybalski, W., editor, Tagnon, H., editor, Tissières, A., editor, Uehlinger, E., editor, Wissler, R. W., editor, Rentchnick, P., editor, Senn, H. J., editor, Mathé, Georges, editor, and Muggia, Franco M., editor

Published
1980
Full Text
View/download PDF

19. Evaluation and Role of Single Chemotherapeutic Agents in Adult Non-Hodgkin’s Lymphoma

Author

Davis, H. L., Von Hoff, D. D., Allfrey, V. G., editor, Allgöwer, M., editor, Bauer, K. H., editor, Berenblum, I., editor, Bergel, F., editor, Bernard, J., editor, Bernhard, W., editor, Blokhin, N. N., editor, Bock, H. E., editor, Braun, W., editor, Bucalossi, P., editor, Chaklin, A. V., editor, Chorazy, M., editor, Cunningham, G. J., editor, Porta, G. Della, editor, Denoix, P., editor, Dulbecco, R., editor, Eagle, H., editor, Eker, R., editor, Good, R. A., editor, Grabar, P., editor, Harris, R. J. C., editor, Hecker, E., editor, Herbeuval, R., editor, Higginson, J., editor, Hueper, W. C., editor, Isliker, H., editor, Kieler, J., editor, Kirsten, W. H., editor, Klein, G., editor, Koprowski, H., editor, Koss, L. G., editor, Martz, G., editor, Mathé, G., editor, Mühlbock, O., editor, Nakahara, W., editor, Old, L. J., editor, Potter, V. R., editor, Sabin, A. B., editor, Sachs, L., editor, Saxén, E. A., editor, Schmidt, C. G., editor, Spiegelman, S., editor, Szybalski, W., editor, Tagnon, H., editor, Taylor, R. M., editor, Tissières, A., editor, Uehlinger, E., editor, Wissler, R. W., editor, Rentchnick, P., editor, Mathé, Georges, editor, Seligmann, Maxime, editor, and Tubiana, Maurice, editor

Published
1978
Full Text
View/download PDF

20. Role of Antitumor Antibiotics in Current Oncologic Practice

Author

Davis, H. L., Jr., Von Hoff, D. D., Henney, J. E., Rozencweig, M., Allfrey, V. G., editor, Allgöwer, M., editor, Bauer, K. H., editor, Berenblum, I., editor, Bergel, F., editor, Bernard, J., editor, Bernhard, W., editor, Blokhin, N. N., editor, Bocke, H. E., editor, Braun, W., editor, Bucalossi, P., editor, Chaklin, A. V., editor, Chorazy, M., editor, Cunningham, G. J., editor, Della Porta, G., editor, Denoix, P., editor, Dulbecco, R., editor, Eagle, H., editor, Eker, R., editor, Good, R. A., editor, Grabar, P., editor, Harris, R. J. C., editor, Hecker, E., editor, Herbeuval, R., editor, Higginson, J., editor, Hueper, W. C., editor, Isliker, H., editor, Kieler, J., editor, Kirsten, W. H., editor, Klein, G., editor, Koprowski, H., editor, Koss, L. G., editor, Martz, G., editor, Mathé, G., editor, Mühlbock, O., editor, Nakahara, W., editor, Old, L. J., editor, Potter, V. R., editor, Sabin, A. B., editor, Sachs, L., editor, Saxén, E. A., editor, Schmidt, C. G., editor, Spiegelman, S., editor, Szybalski, W., editor, Tagnon, H., editor, Taylor, R. M., editor, Tissières, A., editor, Uehlinger, E., editor, Wissler, R. W., editor, Rentchnick, P., editor, Carter, S. K., editor, Umezawa, Hamao, editor, Douros, John, editor, and Sakurai, Yoshio, editor

Published
1978
Full Text
View/download PDF

22. Expanded analyses of NAPOLI-1 : Phase 3 study of nal-IRI (MM-398), with or without 5-fluorouracil (5FU) and leucovorin (LV), versus 5-fluorouracil and leucovorin (5FU/LV), in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based the

Author

Siveke, Jens, Chen, L. T., Von Hoff, D. D., Li, C.-P., Wang-Gillam, A., Bodoky, G., Dean, A., Shan, Y. S., Jameson, G., Macarulla, T., Lee, K. H., Cunningham, D., Blanc, J. F., Hubner, R. A., Chiu, C. F., Schwartsmann, G., Braiteh, F., Moyo, V., Belanger, B., and Bayever, E.

Subjects
Medizin, ComputingMethodologies_GENERAL
Abstract

Poster-Abstract

Published
2016

24. Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas

Author

Ramanathan, R. K., Goldstein, D., Korn, R. L., Arena, F. P, Moore, M., Siena, S., Teixeira, L., Tabernero, Josep, Van Laethem, J.-L., Liu, H., McGovern, D., Lu, B., Von Hoff, D. D., and Universitat Autònoma de Barcelona

Subjects
0301 basic medicine, Oncology, Male, positron emission tomography, endocrine system diseases, pancreatic cancer, metabolic response, Deoxycytidine, nab-paclitaxel, chemistry.chemical_compound, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Metastasis, Aged, 80 and over, medicine.diagnostic_test, Hematology, Middle Aged, medicine.anatomical_structure, Treatment Outcome, Paclitaxel, Positron emission tomography, Response Evaluation Criteria in Solid Tumors, 030220 oncology & carcinogenesis, Adenocarcinoma, Female, Pancreas, medicine.drug, Adult, medicine.medical_specialty, Nab-paclitaxel, Disease-Free Survival, Drug Administration Schedule, Nab -paclitaxel, 03 medical and health sciences, Internal medicine, Pancreatic cancer, Albumins, Gastrointestinal Tumors, medicine, Humans, Letters to the Editor, Aged, business.industry, Metabolic response, Original Articles, medicine.disease, Gemcitabine, Cancérologie, Pancreatic Neoplasms, 030104 developmental biology, chemistry, Positron-Emission Tomography, business, Hématologie
Abstract

In the phase III MPACT trial, nab-paclitaxel plus gemcitabine (nab-P + Gem) demonstrated superior efficacyversus Gem alone for patients with metastatic pancreatic cancer. We sought to examine the feasibility of positron emissiontomography (PET) and to compare metabolic response rates and associated correlations with efficacy in the MPACT trial.Patients and methods: Patients with previously untreated metastatic adenocarcinoma of the pancreas were randomized1:1 to receive nab-P + Gem or Gem alone. Treatment continued until disease progression by RECIST or unacceptable toxicity.Results: PET scans were carried out on the first 257 patients enrolled at PET-equipped centers (PET cohort). Most patients(252 of 257) had ≥ 2 PET-avid lesions, and median maximum standardized uptake values at baseline were 4.6 and 4.5 in thenab-P + Gem and Gem-alone arms, respectively. In a pooled treatment arm analysis, a metabolic response by PET (best responseat any time during study) was associated with longer overall survival (OS) (median 11.3 versus 6.9 months; HR, 0.56;P < 0.001). Efficacy results within each treatment arm appeared better for patients with a metabolic response. The metabolicresponse rate (best response and week 8 response) was higher for nab-P + Gem (best response: 72% versus 53%,P = 0.002; week 8: 67% versus 51%; P = 0.014). Efficacy in the PET cohort was greater for nab-P + Gem versus Gem alone,including for OS (median 10.5 versus 8.4 months; hazard ratio [HR], 0.71; P = 0.009) and ORR by RECIST (31% versus 11%;P < 0.001).Conclusion: Pancreatic lesions were PET avid at baseline, and the rate of metabolic response was significantly higher fornab-P + Gem versus Gem alone at week 8 and for best response during study. Having a metabolic response was associatedwith longer survival, and more patients experienced a metabolic response than a RECIST-defined response.ClinicalTrials.gov: NCT00844649., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2015

25. Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team

Author

Von Hoff, D. D., Goodwin, A. L., and Garcia, L.

Subjects
Male, Antimetabolites, Antineoplastic, Clinical Trials as Topic, Guanine, Antineoplastic Agents, Pemetrexed, Deoxycytidine, Gemcitabine, Pancreatic Neoplasms, Glutamates, Humans, Female, Fluorouracil, Capecitabine, Research Article
Abstract

Pancreatic cancer is a major cause of death from cancer in both men and women in the USA and Europe. The disease causes pain and has a significant impact on the performance status of the patient. In a randomized trial vs 5-fluorouracil, the novel nucleoside analogue gemcitabine (GEMZAR) has been shown to provide clinical benefit for patients (decreased pain and improved performance status) as well as to improve the time to tumour progression and survival for patients with the disease. There are also other new agents that are presented in this discussion, such as the multi-targeted antifolate MTA, capecitabine and the ONYX-015 adenovirus, which replicates in, and kills, only p53-abnormal cells, which have the potential to have an impact on this terrible disease.

Published
1998

27. nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

Author

Goldstein, D., primary, El-Maraghi, R. H., additional, Hammel, P., additional, Heinemann, V., additional, Kunzmann, V., additional, Sastre, J., additional, Scheithauer, W., additional, Siena, S., additional, Tabernero, J., additional, Teixeira, L., additional, Tortora, G., additional, Van Laethem, J.-L., additional, Young, R., additional, Penenberg, D. N., additional, Lu, B., additional, Romano, A., additional, and Von Hoff, D. D., additional

Published
2015
Full Text
View/download PDF

30. Current and Future Management of Testicular Cancer

Author

Muggia, F. M., primary, Barrett, A., additional, Golbey, R. B., additional, von Hoff, D. D., additional, Merrin, C., additional, Skinner, D. G., additional, van der Werf-Messing, B. H. P., additional, and Williams, S. D., additional

Published
1980
Full Text
View/download PDF

31. Palliative surgery in advanced pancreatic cancer

Author

Gouma, Dirk J., Busch, Oliver R. C., van Gulik, Thomas M., von Hoff, D. D., Evans, D. B., Hruban, R. H., Surgery, Amsterdam Gastroenterology Endocrinology Metabolism, and Cancer Center Amsterdam

Published
2005

32. Pathology of the exocrine pancreas

Author

Offerhaus, G. J. A., van Eeden, S., von Hoff, D. D., Evans, D. B., Hruban, R. H., Cancer Center Amsterdam, and Pathology

Published
2005

34. Tumors of th endocrine system

Author

van Eeden, S., Offerhaus, G. J. A., von Hoff, D. D., Evans, D. B., Hruban, R. H., Pathology, and Cancer Center Amsterdam

Published
2005

36. Influence of Primary Pancreatic Tumor Location on Efficacy and Treatment Exposure in the Mpact Trial of Nab-Paclitaxel (Nab-P) Plus Gemcitabine (Gem) Vs Gem Alone for Patients with Metastatic Pancreatic Cancer (Mpc)

Author

Ma, W.W., primary, López-Martín, J.A., additional, Karapetis, C.S., additional, Balcke, P., additional, Kennecke, H., additional, Stahl, M., additional, Milella, M., additional, Nugent, F., additional, Prager, D., additional, Lu, B., additional, Ferrara, S., additional, Penenberg, D., additional, and Von Hoff, D. D, additional

Published
2014
Full Text
View/download PDF

38. A phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors.

Author

Von Hoff, D. D., primary, LoRusso, P., additional, Demetri, G. D., additional, Weiss, G. J., additional, Shapiro, G., additional, Ramanathan, R. K., additional, Ware, J. A., additional, Raja, R., additional, Jin, J., additional, Levy, G. G., additional, Mazina, K. E., additional, and Wagner, A. J., additional

Published
2011
Full Text
View/download PDF

44. Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86-9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer.

Author

Gore, L., primary, Lewis, K., additional, Von Hoff, D. D., additional, Weiss, G. J., additional, Ramanathan, R. K., additional, Adjei, A. A., additional, Dy, G. K., additional, Ma, W. W., additional, Clendeninn, N. J., additional, Leffingwell, D. P., additional, Sheedy, B., additional, Iverson, C., additional, Miner, J. N., additional, Shen, Z., additional, Yeh, L., additional, Dubowy, R. L., additional, Jeffers, M., additional, Rajagopalan, P., additional, and Weekes, C. D., additional

Published
2011
Full Text
View/download PDF

45. ChemInform Abstract: Novel Non-Cross Resistant Diaminoanthraquinones as Potential Chemotherapeutic Agents.

Author

JIANG, J. B., primary, JOHNSON, M. G., additional, DEFAUW, J. M., additional, BEINE, T. M., additional, BALLAS, L. M., additional, JANZEN, W. P., additional, LOOMIS, C. R., additional, SELDIN, J., additional, COFIELD, D., additional, ADAMS, L., additional, CIANCIOLO, G., additional, DEGEN, D., additional, and VON HOFF, D. D., additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results